

GeoVax Labs, Inc.  
Form SC 13D/A  
January 05, 2017

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
SCHEDULE 13D  
Under the Securities Exchange Act of 1934  
(Amendment No. 3)\*

GEOVAX LABS, INC.  
(Name of Issuer)  
Common Stock  
(Title of Class of Securities)  
373678200  
(CUSIP Number)

Robert T. McNally  
President and Chief Executive Office  
1900 Lake Park Drive, Suite 380  
Smyrna, Georgia 30080  
678-384-7220

(Name, Address and Telephone Number of Person  
Authorized to Receive Notices and Communications)  
December 22, 2016

(Date of Event which Requires Filing of this Statement)  
If the filing person has previously filed a statement on  
Schedule 13G to report the acquisition that is the subject of  
this Schedule 13D, and is filing this schedule because of  
ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the  
following box. [ ]

Note: Schedules filed in paper format shall include a signed  
original and five copies of the schedule, including all  
exhibits. See ss.240.13d-7 for other parties to whom copies are to  
be sent.

\* The remainder of this cover page shall be filled out for a  
reporting person's initial filing on this form with respect to  
the subject class of securities, and for any subsequent  
amendment containing information which would alter disclosures  
provided in a prior cover page.

The information required on the remainder of this cover page  
shall not be deemed to be "filed" for the purpose of Section 18  
of the Securities Exchange Act of 1934 ("Act") or otherwise  
subject to the liabilities of that section of the Act but shall  
be subject to all other provisions of the Act (however, see the  
Notes).

CUSIP No. 373678200

1.

NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF  
ABOVE PERSONS (ENTITIES ONLY)

Emory University

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
(see instructions)

Edgar Filing: GeoVax Labs, Inc. - Form SC 13D/A

- (a) [ ]
- (b) [X]

3.

SEC USE ONLY

4.

SOURCE OF FUNDS (see instructions)

00

5.

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED  
PURSUANT TO ITEMS 2(d) or 2(e) [ ]

6.

CITIZENSHIP OR PLACE OF ORGANIZATION

United States (State of Georgia)

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON WITH

7.

SOLE VOTING POWER

4,621,405

8.

SHARED VOTING POWER

Not Applicable

9.

SOLE DISPOSITIVE POWER

4,621,405

10.

SHARED DISPOSITIVE POWER

Edgar Filing: GeoVax Labs, Inc. - Form SC 13D/A

Not Applicable

11.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,621,405

12.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

(see instructions) [ ]

13.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

8.4%

14.

TYPE OF REPORTING PERSON (see instructions)

00

Item 1. Security and Issuer.

Common stock, \$0.001 par value, of GeoVax Labs, Inc. (the "Issuer"). The Issuer's address is 1900 Lake Park Drive, Suite 380 Smyrna, Georgia 30080.

Item 2. Identity and Background.

(a) This statement is filed by Emory University (the "Reporting Person").

(b) The Reporting Person's business address is Administration Building 101, 201 Dowman Drive, Atlanta, Georgia 30322.

(c) The Reporting Person is a private, non-profit educational institution organized under the laws of the State of Georgia.

(d) During the last five years, the Reporting Person has not been convicted in a criminal proceeding.

(e) During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body competent jurisdiction and as a result of such proceeding was or is subject to a judgement, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect

## Edgar Filing: GeoVax Labs, Inc. - Form SC 13D/A

to such laws.

Item 3. Source or Amount of Funds or Other Consideration.

The Reporting Person was issued a total of 233,905,253 shares of the Issuer's common stock in connection with a merger that took place on September 28, 2006 by and between Dauphin Technology, Inc., GeoVax, Inc. and GeoVax Acquisition Corp. Upon completion of the merger, Dauphin Technology, Inc. (now GeoVax Labs, Inc.) issued shares of its common stock, \$0.001 par value, to the shareholders of GeoVax, Inc. in exchange for their issued and outstanding shares of GeoVax, Inc. common stock. Prior to the merger, the Reporting Person was a holder of 7,888,320 shares of GeoVax, Inc. common stock (or securities convertible into GeoVax, Inc. common stock). The securities in GeoVax, Inc. were issued to the Reporting Person in exchange for the license of certain technology owned by the Reporting Person and for cash in the amount of \$750,071.28, which were the personal funds of the Reporting Person.

Item 4. Purpose of Transaction.

The purpose of the September 2006 transaction was to effectuate the merger between Dauphin Technology, Inc. and GeoVax, Inc. The acquisition of the shares in 2006 was done solely in conjunction with the merger. As of the date of this report, the Reporting Person does not have any plan or proposal:

(i) to acquire additional securities of the Issuer or to dispose of securities of the Issuer, although it may do either of these in the future;

(ii) that would result in an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

(iii) that would result in the sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

(iv) to change the composition of the Issuer's board of directors or management, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

(v) that would result in any material change in the present capitalization or dividend policy of the Issuer;

(vi) that would result in any other material change in the Issuer's business or corporate structure;

(vii) that would result in any change in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

(viii) that would cause a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

(ix) that would cause a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or

(x) that would result in any action similar to those enumerated above.

Item 5. Interest in Securities of the Issuer.

On December 22, 2016, the Reporting Person owned 4,621,405 shares, or approximately 8.37%, of the Issuer's common stock. The Reporting Person's dilution in ownership resulted solely from a change in the aggregate number of outstanding securities.

The Reporting Person has the sole power to vote and to dispose

## Edgar Filing: GeoVax Labs, Inc. - Form SC 13D/A

of the shares it beneficially owns; however, the shares owned by the Reporting Person are restricted as the Reporting Person is an Affiliate of the Issuer. The Reporting Person did not effect any transactions in the Issuer's common stock during the past 60 days. No other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the Reporting Person's common stock. The name of the person who has voting or investment control over the securities owned by the Reporting Person is Mary Cahill.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

Not applicable.

Item 7. Material to Be Filed as Exhibits.

Not applicable.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

### COMPANY NAME

By: /s/ Mary L. Cahill  
Mary L. Cahill,  
VP of Investments and CIO

1/5/2017